Media coverage about Veracyte (NASDAQ:VCYT) has trended positive this week, Accern Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Veracyte earned a media sentiment score of 0.26 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.6162011406005 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Several equities research analysts have recently issued reports on VCYT shares. BTIG Research set a $13.00 target price on shares of Veracyte and gave the stock a “buy” rating in a report on Monday, November 20th. Piper Jaffray Companies restated a “hold” rating and issued a $5.40 target price on shares of Veracyte in a report on Thursday, March 1st. Zacks Investment Research lowered shares of Veracyte from a “hold” rating to a “sell” rating in a report on Tuesday, March 6th. Finally, ValuEngine lowered shares of Veracyte from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. Veracyte has a consensus rating of “Hold” and an average target price of $10.78.

Shares of Veracyte (NASDAQ VCYT) traded down $0.14 on Wednesday, reaching $6.25. 15,701 shares of the company were exchanged, compared to its average volume of 111,516. Veracyte has a one year low of $5.23 and a one year high of $9.80. The company has a market cap of $225.98, a price-to-earnings ratio of -6.87 and a beta of 1.61. The company has a quick ratio of 4.04, a current ratio of 4.49 and a debt-to-equity ratio of 0.68.

ILLEGAL ACTIVITY NOTICE: “Veracyte (VCYT) Receives Daily Media Impact Score of 0.26” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at

Veracyte Company Profile

Veracyte, Inc is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis.

Insider Buying and Selling by Quarter for Veracyte (NASDAQ:VCYT)

Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with's FREE daily email newsletter.